Meeting
2012 ASCO Annual Meeting
Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE).
Authors
Ghazaleh Tabatabai
Department of Neurology, University Hospital Zurich, Zurich, Switzerland
Ghazaleh Tabatabai , Michael Weller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01443676
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS2105)
DOI
10.1200/jco.2012.30.15_suppl.tps2105
Abstract #
TPS2105
Poster Bd #
20D
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.
First Author: Hans-Georg Wirsching
Poster
2014 ASCO Annual Meeting
Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).
First Author: Shyam Kumar Tanguturi
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger
Poster
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
First Author: A. M. P. Omuro